Iron deficiency and ferroptosis in gynecology. Possible corrections: A review of the literature

Cover Page

Cite item

Full Text

Abstract

The review presents the main aspects of iron deficiency anemia (IDA) in women of reproductive age and highlights current diagnostic methods, therapy, and prevention of IDA. Moreover, the paper presents contemporary views on the molecular mechanisms of iron metabolism and iron homeostasis disruption involved in endometriosis. The role of laboratory tests in the diagnosis of latent and symptomatic iron deficiency of extreme importance was also described. In addition to IDA, anemia also occurs in patients with chronic gynecological diseases with a different pathogenesis. Its mechanisms were reported in the study discussed in the review. The results of the study on ferroptosis in patients with endometriosis were demonstrated, which showed significantly levels of iron, ferritin, lipid hydroperoxide, and low-density lipoprotein were higher in the peritoneal fluid of women with endometriosis than in healthy women. The paper provided current information on the treatment of IDA in gynecology, possible symptomatic hypophosphatemia after intravenous therapy with iron-containing drugs, and methods to treat this complication. Current data on ferroptosis, its effect on the body, and ways of inducing, and inhibiting this process were presented.

About the authors

Lyudmila A. Ozolinya

N.I. Pirogov Russian National Medical Research University

Author for correspondence.
Email: ozolinya@yandex.ru
ORCID iD: 0000-0002-2353-123X
SPIN-code: 9407-9014

MD, Dr. Sci. (Med.), Professor

Russian Federation, 1, Ostrovityanova str.,117198, Moscow

Sona E. Mamedli

N.I. Pirogov Russian National Medical Research University

Email: sonya_fatima123@mail.ru
ORCID iD: 0000-0002-7769-208X

student

Russian Federation, 1, Ostrovityanova str.,117198, Moscow

Khushnuda A. Bakhodurova

N.I. Pirogov Russian National Medical Research University

Email: xbaxodurova@mail.ru
ORCID iD: 0000-0001-9533-4051

student

Russian Federation, 1, Ostrovityanova str.,117198, Moscow

References

  1. Elstrott B, Khan L, Olson S, et al. The role of iron repletion in adult iron deficiency anemia and other diseases. Eur J Haematol. 2020;104(3):153–161. doi: 10.1111/ejh.13345
  2. Kalinkina OB, Tezikov YuV, Lipatov IS. Management tactics of patients with hyperplastic syndrome and anemia. Medical and Pharmaceutical Journal “Pulse”. 2022;24(5):122–127. (In Russ).doi: 10.26787/nydha-2686-6838-2022-24-5-122-127
  3. Breymann C, Auerbach M. Iron deficiency in gynecology and obstetrics: clinical implications and management. Hematology Am Soc Hematol Educ Program. 2017;2017(1):152–159.doi: 10.1182/asheducation-2017.1.152
  4. Dobrokhotova YuE, Khlynova SA. Correction of Iron Deficiency Anemia in Gynecological Patients. Lechebnoe delo. 2017;(3):31–36. (In Russ).
  5. Dobroсhotova YuE, Karanasheva AKh. Antianemic Treatment of Patients with Submucosal Uterine Myoma after Uterine Artery Embolization. Lechebnoe delo. 2021;(4):52–56. (In Russ). doi: 10.24412/2071-5315-2021-12393
  6. Bolotova EV, Dudnikova AV, Krutova VA. Frequency and features of iron-deficient conditions in women of reproductive age. Clinical Medicine (Russian Journal). 2020;98(4):287–293. (In Russ).doi: 10.30629/0023-2149-2020-98-4-287-293
  7. Dixon SJ, Stockwell BR. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072.doi: 10.1016/j.cell.2012.03.042
  8. Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369–379. doi: 10.1038/cdd.2015.158
  9. DeLoughery TG. Iron Deficiency Anemia. Med Clin North Am. 2017;101(2):319–332. doi: 10.1016/j.mcna.2016.09.004
  10. Briguglio M, Hrelia S, Malaguti M, et al. The Central Role of Iron in Human Nutrition: From Folk to Contemporary Medicine. Nutrients. 2020;12(6):1761. doi: 10.3390/nu12061761
  11. Surzhikova GS, Klochkova-Abelyants SA. Proteins-regulators of iron metabolism in the differential diagnosis of iron-deficiency anemia. Medicine in Kuzbass. 2022;(3):36–40. (In Russ).doi: 10.24412/2687-0053-2022-3-36-40
  12. Lv J, Hou B, Song J, Xu Y, Xie S. The Relationship Between Ferroptosis and Diseases. J Multidiscip Healthc. 2022;15:2261–2275. doi: 10.2147/JMDH.S382643
  13. Vartanian AA. Iron metabolism, ferroptosis and cancer. Russian Journal of Biotherapy. 2017;16(3):14–20. (In Russ).doi: 10.17650/1726-9784-2017-16-3-14-20
  14. Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3(3):285–296. doi: 10.1016/s1535-6108(03)00050-3
  15. Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15(3):234–245. doi: 10.1016/j.chembiol.2008.02.010
  16. Bedford MR, Ford SJ, Horniblow RD, Iqbal TH, Tselepis Ch. Iron chelation in the treatment of cancer: a new role for deferasirox? J Clin Pharmacol. 2013;53(9):885–891. doi: 10.1002/jcph.113
  17. Ludwig H, Evstatiev R, Kornek G, et al. Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr. 2015;127(23–24):907–919. doi: 10.1007/s00508-015-0842-3
  18. Li K, Reichmann H. Role of iron in neurodegenerative diseases. J Neural Transm (Vienna). 2016;123(4):389–399.doi: 10.1007/s00702-016-1508-7
  19. Yu H, Guo P, Xie X, et al. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J Cell Mol Med. 2017;21(4):648–657. doi: 10.1111/jcmm.13008
  20. Ng SW, Norwitz SG, Taylor HS, Norwitz ER. Endometriosis: The Role of Iron Overload and Ferroptosis. Reprod Sci. 2020;27(7):1383–1390. doi: 10.1007/s43032-020-00164-z
  21. Li Y, Zeng X, Lu D, et al. Erastin induces apoptosis via ferroportin-mediated iron accumulation in endometriosis. Hum Reprod. 2021;36(4):951–964. doi: 10.1093/humrep/deaa363
  22. National Hematology Society, National Society of Pediatric Hematologists and Oncologists. Zhelezodefitsitnaya anemiya. Klinicheskie rekomendatsii (approved by the Ministry of Health of the Russian Federation in 2021).Available from: JDA_2021_klin_rek.pdf (In Russ).
  23. Daru J, Colman K, Stanworth SJ, et al. Serum ferritin as an indicator of iron status: what do we need to know? Am J Clin Nutr. 2017;106 Suppl.6:1634S–1639S. doi: 10.3945/ajcn.117.155960
  24. Camaschella C. New insights into iron deficiency and iron deficiency anemia. Blood Rev. 2017;31(4):225–233.doi: 10.1016/j.blre.2017.02.004
  25. Lukina EA, Ledina AV, Rogovskaya SI. Iron-deficiency anemia: a view of hematologist and gynecologist. Optimizing diagnostic and treatment approach. Russian Journal of Woman and Child Health. 2020;3(4):248–253. (In Russ).doi: 10.32364/2618-8430-2020-3-4-248-253
  26. Bouri S, Martin J. Investigation of iron deficiency anaemia. Clin Med (Lond). 2018;18(3):242–244.doi: 10.7861/clinmedicine.18-3-242
  27. Ozolinya LA, Boldina EB. Treatment of anemia in gynecological patients. Obstetrics and Gynecology. 2010;(6):135–139. (In Russ).
  28. Ozolinya LA, Shirenina AA, Kulinicheva EA. Modern possibilities of iron deficiency anemia treatment in one visit. V.F. Snegirev Archives of Obstetrics and Gynecology. 2019;6(4):185–192. (In Russ). doi: 10.18821/2313-8726-2019-6-4-185-192
  29. Ozolinya LA, Savchenko TN, Golovko ED. Correction of iron deficiency in patients with abnormal uterine bleeding. V.F. Snegirev Archives of Obstetrics and Gynecology. 2022;9(3):173–180. (In Russ). doi: 10.17816/2313-8726-2022-9-3-173-180
  30. Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside ― a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(5):2256–2273.doi: 10.1111/bcp.14643
  31. Yagudina RI, Kulikov AYu, Serpik VG, Gromova OA, Torshin IYu. Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(1):73–86. (In Russ).doi: 10.17749/2070-4909/farmakoekonomika.2022.124
  32. Borisova LM, Golubeva IS, Kiseleva MP. Molecular determinants of ferroptosis. Siberian Medical Journal. 2019;158(3):11–16. (In Russ). doi: 10.34673/ismu.2020.49.16.002
  33. Maldonado EN, Sheldon KL, DeHart DN, et al. Voltage-dependent anion channels modulate mitochondrial metabolism in cancer cells: regulation by free tubulin channels modulate mitochondrial metabolism in cancer cells: regulation by free tubulin and erastin. J Biol Chem. 2013;288(17):11920–11929.doi: 10.1074/jbc.M112.433847
  34. Huo H, Zhou Z, Qin J, et al. Erastin disrupts mitochondrial permeability transition pore (mPTP) and induces apoptotic death of colorectal cancer cells. PLoS One. 2016;11(5):e0154605.doi: 10.1371/journal.pone.0154605
  35. Ooko E, Saeed ME, Kadioglu O, et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine. 2015;22(11):1045–1054.doi: 10.1016/j.phymed.2015.08.002

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2023 Eco-Vector



Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).